{"_wandb":{"runtime":0},"_step":0,"study_name":"Study from Banna 2022.pdf","extracted_data":{"study_name":"Study from Banna 2022.pdf","file_name":"Banna 2022.pdf","metadata":{"version":"1.0","description":"RWE Studies Annotations for Extraction Task","created_at":"2025-03-22T18:08"},"raw_data":{"treatment_regimens":["first-line chemoimmunotherapy","pembrolizumab plus platinum-based chemotherapy"],"countries":["United Kingdom","Switzerland"],"populations":[{"stage_histology":"Stage IIIB/IVA, adenocarcinoma","pdl1_status":"PD-L1 negative","n":164},{"pdl1_status":"PD-L1 negative","n":171,"stage_histology":"Stage IVB, adenocarcinoma"},{"stage_histology":"Stage IIIB/IVA, squamous","pdl1_status":"PD-L1 positive","n":51}],"results":{"os_12_month":"52.2%","treatment_specific_results":{"first-line chemoimmunotherapy":{"median_os":"12.7 months","median_pfs":"8.0 months"}},"group_difference":"p D0.001","median_os":"12.7 months","median_rw_pfs":"8.0 months","median_pfs":"8.0 months"}}},"status":"success","_timestamp":1.742663297132125e+09,"_runtime":0.601525}